- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
FTC Requests Further Information on Potential Pfizer Takeover of Seagen
Demand comes among antitrust agency’s recent denial of Amgen’s Horizon buyout.
The Federal Trade Commission (FTC) has asked for more information on Pfizer’s proposed $43 billion takeover of Seagan, a biotechnology company. The request, which comes after the agency’s shutdown of Amgen’s attempt to purchase Horizon Therapeutics for $27.8 billion, has made investors skittish at the potential outcome.
Despite the request, Seagan continues to expect its merger with Pfizer will be completed in late 2023 or early 2024.
Reference: US FTC Seeks Additional Info on Pfizer's Proposed Takeover of Seagen. Reuters. July 14, 2023. Accessed July 17, 2023. https://www.reuters.com/markets/deals/us-ftc-seeks-additional-info-pfizers-proposed-takeover-seagen-2023-07-14/
Transforming Cancer Care: Data, AI, and Patient-Centered Care
July 20th 2023Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.
